Literature DB >> 29472192

Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?

John H Powers1, Scott R Evans2, Aaron S Kesselheim3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29472192     DOI: 10.1136/bmj.k587

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Authors:  Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Samuel P Simon; Sahil Bhatia; Sarah M Melvin; Molly E Steed; Natalie A Finch; Taylor Morrisette; Sandy J Estrada; Joshua R Rosenberg; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018.

Authors:  Aida Kuzucan; John H Powers; Peter Doshi
Journal:  Mayo Clin Proc       Date:  2020-12       Impact factor: 7.616

3.  Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa.

Authors:  Sara Alosaimy; Abdalhamid M Lagnf; Taylor Morrisette; Marco R Scipione; Jing J Zhao; Sarah C J Jorgensen; Ryan Mynatt; Travis J Carlson; Jinhee Jo; Kevin W Garey; David Allen; Kailynn DeRonde; Ana D Vega; Lilian M Abbo; Veena Venugopalan; Vasilios Athans; Stephen Saw; Kimberly C Claeys; Mathew Miller; Kyle C Molina; Michael Veve; Wesley D Kufel; Lee Amaya; Christine Yost; Jessica Ortwine; Susan L Davis; Michael J Rybak
Journal:  Open Forum Infect Dis       Date:  2021-07-14       Impact factor: 3.835

Review 4.  Designing development programs for non-traditional antibacterial agents.

Authors:  John H Rex; Holly Fernandez Lynch; I Glenn Cohen; Jonathan J Darrow; Kevin Outterson
Journal:  Nat Commun       Date:  2019-07-31       Impact factor: 14.919

5.  Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

Authors:  Marlieke E A de Kraker; Harriet Sommer; Femke de Velde; Isaac Gravestock; Emmanuel Weiss; Alexandra McAleenan; Stavros Nikolakopoulos; Ohad Amit; Teri Ashton; Jan Beyersmann; Leonhard Held; Andrew M Lovering; Alasdair P MacGowan; Johan W Mouton; Jean-François Timsit; David Wilson; Martin Wolkewitz; Esther Bettiol; Aaron Dane; Stephan Harbarth
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.